TPH2 and major depressive disorder: Second, it includes both healthy participants and MDD patients, allowing us to investigate potential associations unique to healthy or pathological states; third, in our analyses we included blood cells proportions, which has rarely been done in former studies evaluating methylation at SLC6A4 or TPH2 and can be the main driver of methylation variability across individuals [39, 85].